Drugs / BMS-833923
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT01413906 | Nov 2011 → Nov 2012 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00927875 | Feb 2010 → Sep 2012 | small cell lung carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00909402 | Nov 2009 → Nov 2012 | gastric neoplasm, neoplasm of esophagus | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00884546 | Jul 2009 → Mar 2012 | cancer of unknown primary site | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00670189 | Jul 2008 → Apr 2014 | basal cell carcinoma, nevoid basal cell carcinoma syndrome | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01218477 | Jan 2011 → Apr 2013 | leukemia | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01357655 | Sep 2011 → Jan 2016 | myeloid leukemia | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Enrollment |
| Phase not applicable1 trial | ||||||
| — | NCT02100371 | Feb 2014 → May 2017 | nevoid basal cell carcinoma syndrome | University Health Network, Toronto | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-833923 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00909402 ↗ |
| Known as | BMS-833923 FREE BASE ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545403 ↗ |
| Known as | XL139 | “A Phase 1b Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-833923 (XL139) in Combination With Carboplatin and Etoposide...” NCT00927875 ↗3“Phase 1b Multiple Ascending Dose Study of BMS-833923 (XL139) Administered in Combination With Cisplatin and Capecitabine as First-Line Therapy in Patients With Inoperable,...” NCT00909402 ↗ “The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule” NCT00670189 ↗ “SMO Inhibitor (BMS-833923; XL139)” NCT01218477 ↗ |
| Action | Inhibit | “SMO Inhibitor (BMS-833923; XL139)” NCT01218477 ↗ |
| Modality | Small molecule | — CHEMBL3545403 ↗ |
| Route | Oral | “Capsules, Oral, 30 mg starting” NCT00670189 ↗ |
| Target | SMO | “Smoothened (SMO) Inhibitor” NCT01218477 ↗ |